An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B

Trial Profile

An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Eftrenonacog alfa (Primary)
  • Indications Haemophilia B
  • Focus Registrational; Therapeutic Use
  • Acronyms B-YOND
  • Sponsors Biogen; Bioverativ
  • Most Recent Events

    • 13 Oct 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
    • 13 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Oct 2017.
    • 10 Sep 2017 This trial has been completed in Poland.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top